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Abstract 
Scope: Cocoa and (-)-epicatechin (EC), a main cocoa flavanol, have been suggested to 
exert beneficial effects in diabetes, but the mechanism for their insulin-like effects 
remains unknown. In this study, the modulation of insulin signalling by EC and a cocoa 
phenolic extract (CPE) on hepatic HepG2 cells was investigated by analysing key 
proteins of the insulin pathways, namely insulin receptor (IR), insulin receptor substrate 
(IRS)-1 and 2, PI3K/AKT and 5´-AMP-activated protein kinase (AMPK), as well as the 
levels of the glucose transporter GLUT-2 and the hepatic glucose production. 
Methods and results: EC and CPE enhanced the tyrosine phosphorylation and total IR, 
IRS-1 and IRS-2 levels and activated the PI3K/AKT pathway and AMPK in HepG2 
cells. CPE also enhanced the levels of GLUT-2. Interestingly, EC and CPE modulated 
the expression of phosphoenolpyruvate carboxykinase, a key protein involved in the 
gluconeogenesis, leading to a diminished glucose production. In addition, EC- and 
CPE-regulated hepatic gluconeogenesis was prevented by the blockage of AKT and 
AMPK. 
Conclusion: Our data suggest that EC and CPE strengthen the insulin signalling by 
activating key proteins of that pathway and regulating glucose production through AKT 
and AMPK modulation in HepG2 cells. 
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1. Introduction 
Diabetes is one of the most common chronic diseases in nearly all countries, and it is 
continuing to be an increasing international health burden [1]. Current medications are 
not adequately effective in maintaining long-term glycemic control in most patients. 
Therefore, there is an urgent need to continue working on the prevention and control of 
diabetes. In this regard, a promising approach is the employ of the natural compounds 
with insulin-like activity, which have been proposed as potential therapeutic agents in 
the prevention and/or treatment of this disease [2]. 
The liver has an important role in the control of the whole body metabolism of energy 
nutrients. In diabetes, the insulin target tissues are damaged, which aggravates the 
ability of insulin to trigger downstream metabolic actions resulting in insulin resistance. 
In this regard, one of the hallmarks of diabetes is the alteration of the hepatic 
metabolism: the liver is not able to control the glucose homeostasis, which is one of the 
causes for the hyperglycemia, and there is a miss-regulation of the insulin pathway in 
this organ [3]. 
Insulin signal transduction is initiated when insulin binds to the insulin receptor (IR), 
which leads to the stimulation of several intracellular protein substrates including 
insulin receptor substrate (IRS)-1 and IRS-2. This triggers the phosphatidylinositol-3-
kinase (PI3K) pathway that stimulates AKT and leads to the inhibition of glycogen 
synthase kinase-3 (GSK-3) by phosphorylation, which subsequently phosphorylates and 
inactivates glycogen synthase (GS), and conducts to the modulation of other proteins 
necessary for the acute metabolic effects of insulin [3]. In addition, in the hepatocyte 
AKT might phosphorylate the transcription factor forkhead box protein O1 (FOXO1), 
restraining the expression of phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pase), and inhibiting the gluconeogenesis [3]. 5´-AMP-
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activated protein kinase (AMPK) also constitutes a central regulator of the cellular 
metabolism, able to suppress the hepatic gluconeogenesis [4]; in fact numerous drugs 
that are in clinical use for treatment of type 2 diabetes activate AMPK [4, 5]. 
(-)-Epicatechin (EC) is one of the most abundant flavonoids in human diet, being 
present in high concentrations in grapes, cocoa, tea, and many other fruit and vegetables 
[6, 7]. Different studies have shown that EC is able to interfere with the 
oxidative/antioxidative potential of hepatic cells [6, 8], induces survival/proliferation 
pathways [8-10], exerts insulin-like activities [11], and improves insulin sensitivity [12], 
blood glucose levels [13] and parameters related to the inflammation in cardiovascular 
disease and diabetes [12, 14, 15]. Similarly, dark chocolate or cocoa, which are widely 
consumed [16] and are a rich source of flavonoids, especially (-)-epicatechin [6], have 
been reported to protect against carcinogenesis [7, 17], improve the allergy process [18], 
cardiovascular status [16, 19, 20], insulin sensitivity and hyperglycemia [19, 21] in 
humans and experimental animals. However, the precise mechanism for the preventive 
activities of EC and cocoa related to glucose metabolism and insulin signalling in the 
liver remains largely unknown. 
The present work evaluates the effects of EC and a cocoa phenolic extract (CPE) on 
insulin signalling pathways and glucose production in HepG2 cells. The study 
demonstrates that EC and CPE have insulinomimetic activities in the human hepatic 
HepG2 cells, as EC and CPE enhanced the tyrosine phosphorylation and total IR, IRS-1 
and IRS-2 levels, which was associated to an activation of the PI3K/AKT pathway and 
AMPK. We have also found that AKT and AMPK are required to modulate the hepatic 
glucose production. 
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2. Materials and methods 
2.1. Materials and chemicals 
(-)-EC (>95% of purity), Compound C (6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyridin-
4-ylpyrazolo[1,5-a]pyrimidine), LY294002 (2-(4-morpholinyl)-8-phenyl-1(4H)-
benzopyran-4-one hydrochloride), anti-mouse IgG-agarose, sodium lactate, sodium 
pyruvate, gentamicin, penicillin G and streptomycin were purchased from Sigma 
Chemical (Madrid, Spain). Cell proliferation ELISA BrdU (colorimetric) assay kit was 
from Roche Diagnostics (Barcelona, Spain). Anti-AKT and anti-phospho-Ser473-AKT 
detecting levels of phospho- and total AKT 1-3, anti-AMPK and anti-phospho-Thr172-
AMPK, as well as anti-GSK3 α/β and anti-phospho-GSK3 α/β recognizing 
phosphorylated Ser21/9 of GSK3, anti-GS and anti-phospho-GS recognizing 
phosphorylated Ser641 of GS, anti-IRS-2 and anti-β-actin were obtained from Cell 
Signalling Technology (Izasa, Madrid, Spain). Anti-IR β, anti-PEPCK and anti-Tyr(P) 
(PY20) were purchased from Santa Cruz (sc-711, sc-32879 and sc-508, respectively, 
Qimigen, Madrid, Spain). Anti-IRS-1 and anti-GLUT-2 were from Millipore (Madrid, 
Spain). Materials and chemicals for electrophoresis were from BioRad (BioRad 
Laboratories S.A., Madrid, Spain). Cell culture dishes and cell culture medium were 
from Falcon (Cajal, Madrid, Spain) and Lonza (Madrid, Spain), respectively.  
 
2.2. Cocoa polyphenol extraction 
Natural Forastero cocoa powder (Nutrexpa, Barcelona, Spain) was used for this study. 
Soluble polyphenols were extracted by sequentially washing 1 g of sample with 40 mL 
of 16 mM hydrochloric acid in 50% aqueous methanol (50:50, v/v, 1 h at room 
temperature, constant shaking) and 40 mL of acetone:water (70:30, v/v, 1 h at room 
temperature, constant shaking). After centrifugation (15 min, 3000 g), supernatants 
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from each extraction step were combined and made up to 100 mL. The desiccated 
extract was dissolved in distilled water and kept frozen until assay. A detailed 
description of this cocoa polyphenol extract (CPE) is given elsewhere [6, 22]. 
Accordingly, the amount of EC and polyphenols present in the CPE were 383.5 
mg/100g (determined by LC-MS) and 2 g/100 g on dry matter basis (determined by 
Folin-Ciocalteu) [6]. Concentrations of EC in tested doses of CPE range from 13.2 nM 
(in the dose of 1 µg CPE/mL) to 132 nM (in that of 10 µg CPE/mL) [6]. 
 
2.3 Cell culture and treatments 
Human HepG2 cells were grown in DMEM-F12 medium supplemented with 2.5% 
foetal bovine serum (FBS) and the following antibiotics: gentamicin, penicillin and 
streptomycin (50 mg/L). Cells were maintained at 37ºC in a humidified atmosphere of 
5% CO2. One day after plating, the medium was changed to DMEM containing 5.5 mM 
D-glucose, 2 mM glutamine and FBS, and the culture was continued. Subsequently, the 
experimental treatment was carried out for the indicated periods with various 
concentrations of EC or CPE in serum-free media containing 5.5 mM D-glucose, 2 mM 
glutamine for 24 h. 
Cells were treated with different concentrations of EC (1-20 M) or CPE (1-20 μg/mL) 
diluted in serum-free culture medium during 24 h. In the experiments with the 
pharmacological inhibitors, cells were preincubated with 25 M LY294002 or 40 M 
Compound C for 1 h prior to 24 h of EC or CPE treatment. 
 
2.4. Cell viability assay 
Cell viability was determined by using the crystal violet assay [8]. HepG2 cells were 
seeded at low density (10
4
 cells per well counted in a Neubauer chamber) in 96-well 
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plates, grown for 20 h and incubated with crystal violet (0.2% in ethanol) for 20 min. 
Plates were rinsed with water, allowed to dry, and 1% sodium dodecylsulfate added. 
The absorbance of each well was measured using a microplate reader at 570 nm. 
 
2.5. Cell proliferation assay (5-bromo-2’-deoxyuridine assay, BrdU) 
A colorimetric immunoassay (ELISA) was used for the quantification of cell 
proliferation [8]. This method is based on the measurement of BrdU incorporation into 
genomic DNA during DNA synthesis of proliferating cells. HepG2 cells were seeded 
(10
4
 cells per well counted in a Neubauer chamber) in 96-well plates, grown 20 h and 
labelled by the addition of BrdU for 4 h. Then the anti-BrdU antibody was added and 
the immune complexes were quantified by measuring the absorbance at 620 nm in a 
microplate reader. 
 
2.6. Preparation of cell lysates 
Cells were lysed at 4ºC in a buffer containing 25 mM HEPES (pH 7.5), 0.3 M NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.1% Trition X-100, 200 mM β-
glycerolphosphate, 0.1 mM Na3VO4, 2 μg/mL leupeptin and 1 mM 
phenylmethylsulfonyl fluoride. The supernatants were collected, assayed for protein 
concentration by using the Bio-Rad (Bio-Rad, Madrid, Spain) protein assay kit 
according to the manufacture´s specifications, aliquoted and stored at -80º C until used 
for immunoprecipitation and/or Western blot analyses. 
 
2.7. Immunoprecipitation 
Protein extracts containing 200 µg of protein were immunoprecipitated overnight at 4ºC 
with gentle rotation in the presence of 2-5 µg of anti-Tyr(P) (PY20) antibody, followed 
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by the addition of anti-mouse IgG-agarose. After mixing for 2 h, the pellets were 
collected by centrifugation, and the supernatants were discarded. Then the pellets were 
washed and saved for Western blot analyses. 
 
2.8. Western blot analysis 
Equal amounts of proteins were separated by SDS-polyacrylamide gel electrophoresis 
and transferred to polyvinylidene difluoride filters (Bio-Rad, Madrid, Spain). 
Membranes were probed with the corresponding primary antibody followed by 
incubation with peroxide-conjugated anti-rabbit (GE Healthcare, Madrid, Spain) or anti-
mouse (Sigma, Madrid, Spain) immunoglobulin. Blots were developed with the ECL 
system (GE Healthcare, Madrid, Spain). Normalization of Western blot was ensured by 
β-actin and bands were quantified using a scanner and accompanying software. 
 
2.9. Glucose production assay 
HepG2 cells were seeded in 24-well plates (2 x 10
5
 cells per well counted in a Neubauer 
chamber) and treated in serum-free DMEM with 10 µM EC or 1 µg/mL CPE for 24 h. 
The medium was then replaced with glucose production buffer consisting of glucose-
free DMEM (pH 7.4), without phenol red (Invitrogen, Madrid, Spain), supplemented 
with 20 mM sodium lactate and 2 mM sodium pyruvate, as previously described [23, 
24]. After a 3-h incubation, medium was collected and glucose concentration measured 
with a colorimetric glucose assay kit (Sigma, Madrid, Spain). The readings were then 
normalized to the total protein content determined from the whole-cell lysates. 
 
2.10. Statistics 
 9 
Prior to statistical analysis, data were tested for homogeneity of variances by the test of 
Levene; for multiple comparisons, one-way ANOVA was followed by the Bonferroni 
test when variances were homogeneous or by the Tamhane test when variances were not 
homogeneous. P<0.05 was considered significant. A SPSS version 19.0 program has 
been used. 
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3. Results 
3.1. Cell viability and proliferation 
To determine the potential effects on cell viability and proliferation of EC and CPE in a 
human hepatic cell line (HepG2), cells were exposed to a range of concentrations (0-20 
µM and 0-20 µg/mL, respectively) for 24 h. 
Treatment of HepG2 cells for 24 h with EC or CPE did not evoke changes in cell 
viability, as determined by the crystal violet assay, indicating that the concentrations 
selected for the study did not damage cell integrity during the period of incubation 
(Table 1). Similarly, treatment with EC or CPE did not affect cell growth, indicating no 
impairment of cell proliferative machinery and preservation of a regular cell cycle 
(Table 1). Since none of the tested doses induced cell toxicity, the lowest and realistic 
range of concentrations was selected for further studies [6, 22]. 
 
3.2. Effects of EC and CPE on tyrosine phosphorylation and protein levels of IR 
and its substrates IRS-1 and IRS-2 
The modulation of IR and its downstream substrates IRS-1 and IRS-2 is essential for 
recruiting and activating downstream pathways [25]. In fact, in hepatic insulin 
resistance the insulin-stimulated-IR and IRS tyrosine phosphorylation is defective and 
results in reduced IRS-associated PI3K activities [3]. To test the effect of EC and CPE 
on tyrosine phosphorylation and total levels of IR and its substrates, HepG2 cells were 
exposed for 24 h to various concentrations of these substances. 
As shown in Figure 1-, IR and IRS-2 phosphorylated and total protein levels equally 
increased with all concentrations of EC and CPE tested, as well as the phosphorylated 
and total protein levels of IRS-1 when cells were incubated with CPE. EC dose-
dependently increased the phosphorylated and total levels of IRS-1 (Figures 1A and 
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1C). All these results suggest that EC and CPE could strengthen the insulin signalling 
cascade by up-regulating the early steps of this pathway. 
 
3.3. Effects of EC and CPE on AKT, GSK3 and GS phosphorylation 
AKT is the molecular key in mediating the metabolic effects of insulin signalling [25]. 
It lays downstream of PI3K and facilitates glucose uptake and glycogen synthesis in the 
liver [25]. To test the modulation of AKT by EC and CPE, phosphorylated and total 
AKT were evaluated in cell lysates by Western blot analysis. As shown in Figures 2A 
and 2B, the treatment of cells with EC and CPE for 24 h increased the phosphorylation 
of AKT with all concentrations tested. EC (10 µM) showed higher levels of p-AKT than 
lower concentrations of EC, whereas all doses of CPE induced a similar enhancement in 
p-AKT values. 
Since AKT directly contributes to the activity of GS [25], the effect of EC and CPE on 
the phosphorylated and total protein expression levels of GSK3 and GS was assayed. 
Western blot analysis of GSK3 and p-GSK3 proteins showed two bands corresponding 
to the α and β isoforms. EC and CPE treatment enhanced the phosphorylated isoforms, 
as illustrated in Figures 2A and 2C. EC (10 µM) induced the highest increase in the 
levels of p-GSK3 in comparison to the other doses of EC, and CPE equally enhanced 
the levels of p-GSK3 with all concentrations assayed, in agreement to what was 
observed for AKT (Figures 2A and 2B).  
As shown in Figures 2A and 2D, p-GS levels decreased in the presence of EC or CPE 
with all concentrations tested. As it could be expected according to the previous results, 
CPE equally diminished the phosphorylated levels of GS and 10 µM EC induced the 
most remarkable diminution of p-GS of all EC concentrations assayed. There was no 
difference in the total levels of AKT, GSK3 and GS. 
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3.4. Effects of EC and CPE on AMPK phosphorylation 
To continue the study of the potential effect of EC and CPE on key proteins of the 
insulin signalling, AMPK, which is a sensor of energy status for maintaining cellular 
energy homeostasis [5], was evaluated by analysing the total and phosphorylated levels 
in total cell lysates by Western blot analysis. Figure 3 illustrates that a 24 h treatment 
with EC or CPE induced an increase in AMPK phosphorylated levels. EC (5 and 10 
µM) showed higher levels of p-AMPK than the lowest concentration of EC, whereas 
CPE induced a similar activation of AMPK with all concentrations tested. The protein 
levels of total AMPK were not modified by EC or CPE treatment. 
 
3.5. Effects of EC and CPE on GLUT-2 protein levels 
The GLUT-2 transporter mediates the diffusion of glucose across the plasma membrane 
of the hepatocyte, maintaining intracellular glucose in equilibrium with extracellular 
glucose [3]. To test whether this transporter was affected by EC and CPE, HepG2 cells 
were incubated with the selected concentrations for 24 h. 
Treatment of HepG2 cells with any of the three concentrations of EC did not affect the 
expression levels of GLUT-2, and only 10 µg/mL CPE increased the levels of GLUT-2 
after a 24 h-incubation (Figure 4). 
 
3.6. Effect of EC and CPE activation of AKT on hepatic gluconeogenesis 
In the liver, insulin-activated AKT inhibits the expression of PEPCK and G6Pase and, 
therefore, gluconeogenesis [3]. In view of the increased levels of p-AKT induced by EC 
and CPE, it was studied whether both substances were able to modulate the expression 
of a major enzyme responsible of the regulation of gluconeogenesis, such as PEPCK, as 
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well as the production of glucose. To this end, HepG2 cells were exposed to a selective 
inhibitor of AKT (LY294002) and EC or CPE and the levels of PEPCK and the novo 
production of glucose were assayed. The concentrations selected for these analyses were 
the doses that exhibited a prominent effect on the activation of the PI3K/AKT pathway, 
i.e.: 10 µM for EC and 1 µg/mL for CPE. 
Treatment of HepG2 cells with EC or CPE showed a comparable decrease in the 
expression of PEPCK (Figures 5A and 5B). LY294002 alone increased the levels of 
PEPCK, although these values decreased by the addition of EC and CPE (Figures 5A 
and 5B). LY294002 treatment decreased p-AKT levels in all cells incubated with this 
inhibitor, although p-AKT values were partly recovered in the presence of EC or CPE 
when compared to untreated cells (Figures 5A and 5C). p-AMPK and total expression 
of AKT and AMPK were not affected by LY294002 (Figures 5A, 5C and 5D). EC and 
CPE decreased the production of glucose (Figure 5E). In addition, the presence of the 
AKT selective inhibitor alone increased the hepatic glucose production, and this 
enhancement was less prominent in LY+EC- and LY+CPE-treated cells (Figure 5E). 
Conversely, LY294002 could not totally block the inhibitory effect of EC and CPE on 
PEPCK and glucose production, indicating that other pathways may also be involved in 
EC- and CPE-induced effects. 
 
3.7. Effect of EC and CPE activation of AMPK on hepatic gluconeogenesis 
AMPK is another known suppressor of hepatic gluconeogenesis [3]. To examine the 
role of AMPK on the modulation of the levels of PEPCK and the production of glucose, 
AMPK was blocked by a selective chemical inhibitor (Compound C) prior to the 
treatment with EC or CPE. As mentioned above, the concentrations selected for these 
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analyses were the previously chosen (10 µM for EC and 1 µg/mL for CPE), since they 
showed a prominent effect on the activation of AMPK. 
As illustrated in Figures 6A and 6B, EC and CPE decreased the levels of PEPCK, and 
the blockage of AMPK induced a significant increase in the expression of the 
mentioned gluconeogenic enzyme. However, this enhancement was less pronounced in 
the presence of EC and CPE in comparison to that induced by the compound C alone. 
Treatment with compound C alone decreased p-AMPK levels, whereas incubation with 
EC or CPE and compound C partly recovered p-AMPK levels (Figures 6A and 6D). p-
AKT and total AKT and AMPK remained unaltered after incubating the cells with 
compound C (Figures 6A, 6C and 6D). In addition, compound C enhanced the glucose 
production via hepatic gluconeogenesis (Figure 6E). Similarly, the increase in glucose 
production was higher in compound C-treated cells than in C+EC- and C+CPE-treated 
cells (Figure 6E). However, compound C could not completely block the inhibitory 
effect of EC and CPE on PEPCK and glucose production, indicating that other 
pathways may also contribute to the beneficial effects of EC and CPE. 
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4. Discussion 
Flavonoids have been found to possess beneficial effects on health and have drawn 
attention because of their safety and accumulating evidence on their antidiabetic effects 
in animals and humans [2]. In the current study, we have demonstrated for the first time 
that EC and CPE enhanced the tyrosine phosphorylated and total IR, IRS-1 and IRS-2 
levels together with an activation of the PI3K/AKT pathway and AMPK (Figure 7). We 
have also provided evidence on the insulin-like activity of EC and CPE, which were 
able to down-regulate the levels of the key gluconeogenic enzyme PEPCK and 
modulate the hepatic glucose production through AKT and AMPK (Figure 7). HepG2 
cells are widely used for biochemical and nutritional studies as a cell culture model of 
human hepatocytes since they retain their morphology and most of their function in 
culture [26-28]. Thus, this cell line has been extensively used to study the hepatic 
glucose production and the modulation of the insulin pathway in vitro [27-30]. 
The liver plays a critical role in maintaining blood glucose concentration both through 
its ability to supply glucose to the circulation via glycogenolysis and gluconeogenesis in 
the postabsorptive state and to remove glucose from the circulation after meal ingestion 
[3]. However, in diabetes the gluconeogenic pathway is aberrantly activated, supplies a 
relatively larger amount of glucose into the circulation [2, 3], and there is also hepatic 
insulin resistance [3]. Therefore, the modulation of the mentioned targets could be 
beneficial for the prevention and control of this disease; in this line, natural compounds 
such as flavonoids could play a major role, although little investigation at the molecular 
level has been performed. 
In the present study it is shown that EC and CPE increased tyrosine phosphorylation 
and total levels of IR and IRS in HepG2 cells. In concert, epigallocatechin gallate 
(EGCG) and naringenin attenuated high glucose-induced signalling blockage by 
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reducing IRS-1 serine phosphorylation in HepG2 cells [27] and by activating IRS-1 in 
primary hepatocytes of mice with metabolic syndrome [31]. In addition, green tea 
polyphenols increased IRS-2 mRNA levels in the liver [32], as well as IR and IRS-1 
and -2 levels in the myocardium of insulin-resistant rats [33]. Similarly, oligomers of a 
grape-seed procyanidin extract increased IR and IRS levels in preadipocytes [34]. In 
this line, the oligomeric structures of the extract activated the IR by interacting with and 
inducing its tyrosine phosphorylation [34]. ECGC and rutin stimulated the IRS2 
signalling by enhancing tyrosine phosphorylation under high glucose condition on 
pancreatic β cells [35], and in 3T3-L1 preadipocytes a CPE did not affect the levels of 
IR but it modulated its IR kinase activity via direct binding [36]. 
The activation of IRS-1/-2 initiates the stimulation of the PI3K/AKT pathway, which is 
needed for the metabolic effects of insulin in the liver and is responsible of the 
inhibition of GSK-3 and activation of GS [3]. In this regard, EC and CPE seemed to 
mimic the metabolic actions of insulin, as they increased the phosphorylated levels of 
AKT and GSK-3, and decreased p-GS values. Previous studies have also demonstrated 
the stimulation of AKT by EC and CPE in HepG2 cells [10, 22], and EC was reported 
to partly reverse the inhibition of AKT phosphorylation induced by high glucose levels 
[27]. Similarly, naringenin activated the AKT pathway in HepG2 cells [29] and green 
tea polyphenols increased the RNA expression levels of PI3K/AKT in the liver of 
insulin-resistant rats [32]. In this line, green tea polyphenols also increased the mRNA 
levels of GSK3 in the liver of insulin-resistant rats [32]. However, a decrease in the 
expression of GSK3 and an increase in the mRNA levels of GS have been reported in 
the myocardium of insulin-resistant rats [33]. All together indicates that polyphenols 
reinforced the signal pathways responsive to insulin. 
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In the liver, GLUT-2 is a glucose-sensitive gene that mediates both influx and efflux of 
glucose across the plasma membrane [3]. In the present study, levels of GLUT-2 were 
induced by the highest concentration of CPE tested, whereas EC did not show any effect 
on the modulation of the protein levels of this transporter. Although the influence of the 
phenolic compounds on the GLUTs has been scarcely evaluated, especially in the liver, 
in agreement with the present results no effects on the mRNA GLUT-2 levels in the 
liver of insulin-resistant rats fed with green tea polyphenols have been reported [32]. 
However, it should be mentioned that, as occurs for 10 µg/mL CPE, the grape 
polyphenol resveratrol and the antidiabetic drugs pioglitazone and rosiglitazone, which 
are peroxisome proliferator-activated receptor (PPAR)-γ agonists, were able to increase 
GLUT-2 expression in β-cells [37, 38]. In this line, our results could suggest that CPE 
could more efficiently contribute to glucose uptake from the blood when glucose levels 
are postprandially elevated in comparison with EC, as described for rosiglitazone [37]. 
This effect has been related to the regulation of PPARγ for rosiglitazone [37], as well as 
to the activation of AKT or AMPK in diabetic animals [39, 40], but further studies are 
needed to elucidate how GLUT-2 is modulated by CPE in hepatic cells. 
AMPK is an important therapeutic target for diabetes as it is one of the central 
regulators of cellular metabolism, which can be activated at least by two pathways: liver 
kinase B1 (LKB1) and Ca
2+
/calmodulin-dependent protein kinase kinase (CaMMK) [5]. 
In the present work, the phosphorylated levels of AMPK increased after incubating 
HepG2 cells with EC and CPE. Interestingly, the major green tea compound EGCG has 
previously been shown to activate AMPK in hepatic cells via CaMMK [23, 27]. In 
addition, other polyphenols such as theaflavins, naringin, anthocyanins, resveratrol and 
apigenin have proved to activate AMPK in the liver of mice and rats and, consequently, 
to modulate cellular metabolism [30, 31, 41, 42]. Similarly, other natural compounds 
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such as berberine, ginsenosides obtained from ginseng and extracts from the plant 
Artemisia sacrorum have been demonstrated to stimulate AMPK in HepG2 cells [43-
46]. 
PEPCK is one of the major enzymes responsible of the regulation of gluconeogenesis 
[3]. In the present work, EC and CPE decreased PEPCK levels in HepG2 cells. In 
agreement with our results, other phenolic compounds such as EGCG, naringenin, 
catechin-rich green tea, naringin, genistein, daidzein and anthocyanins diminished the 
levels of this gluconeogenic enzyme in hepatic cells and mouse liver during an induced 
insulin-resistant situation and, consequently, reduced glucose production [23, 31, 41, 
47-50]. 
AKT and AMPK are known to suppress the gluconeogenesis in the liver [3, 4, 25]. 
Suppression of hepatic gluconeogenesis by AKT-dependent insulin signalling is 
reduced or lost in type 2 diabetes due to insulin resistance plus a relatively insufficient 
insulin production [25]. In addition, activation of AMPK results in enhanced fatty acid 
oxidation and decreased production of glucose, cholesterol and triglycerides in the liver 
[3, 4]. Thus, activation of AMPK supresses G6Pase and PEPCK and then decreases 
hepatic glucose production [3, 4]. In agreement, we have shown that both kinases are 
involved in the modulation of PEPCK levels and the production of glucose in HepG2 
cells treated with EC and CPE (Figure 7). As previously mentioned, EGCG activated 
AMPK and consequently inhibited hepatic gluconeogenesis via AMPK, although AKT 
seemed not to be involved in this process since it was not stimulated by the flavanol 
[23]. Similarly, naringenin did not modify AKT phosphorylation, and the incubation of 
the cells with LY294002 did not suppress the hepatic glucose production [48]. In 
addition, AMPK also mediated naringin repression of hepatic gluconeogenesis [31]. In 
this line, other natural compounds such as berberine, ginesenosides and an extract from 
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Artemisia sacrorum supressed the hepatic glucose production and/or downregulated the 
levels of PEPCK via AMPK, although their effects on the mentioned parameters in the 
presence compound C were weaker than the effect showed by the natural compound 
alone [43-46]. Interestingly, clove extract acted like insulin in HepG2 cells by reducing 
PEPCK gene expression and this feature was reverted by LY294002 [51]. It has also 
been shown that LY294002 inhibited the expression of PEPCK, but AKT did not 
modulate the hepatic production of glucose via gluconeogenesis [23, 49]. Likewise, in 
the present study p-AMPK and p-GSK3β levels were increased by EC and CPE 
incubation. Accordingly, it has been showed that in the liver the activated form of 
AMPK is responsible for metabolic changes via phosphorylation of downstream 
substrates such as GSK3β and cAMP response element binding protein, which are 
directly or indirectly related to glucose production [43, 46]. In this regard, EGCG 
promotes phosphorylation of CaMKK, and blockade of CaMKK activity prevents 
EGCG activation of AMPK and mitigates the inhibitory role of EGCG in hepatic 
gluconeogenesis [23]. 
As mentioned above, cocoa is a rich source of flavonoids such as (-)-EC, (+)-catechin, 
and procyanidins, and EC is the most abundant flavanol in the CPE employed in this 
study [6]. Considering that concentrations of EC in tested doses of CPE range from 13.2 
nM (in the dose of 1 µg CPE/mL) to 132 nM (in that of 10 µg CPE/mL) [6], and CPE 
effects are equivalent to those of the pure flavanol, it is reasonable to assume that EC is 
just one of the many bioactive substances present in CPE and that the synergic effect of 
phenolic compounds in foodstuffs should be taken into account, as previously shown 
[52]. 
It is worth mentioning that the range of concentrations used in the study is not far from 
realistic. In this regard, rats fed with EC showed plasma concentrations of EC and EC 
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metabolites of about 35 µM 1 h after oral administration of 172 µmol EC/Kg body 
weight [53]. In humans, levels of 6 µM EC and 41 nM procyanidin B2 have been 
reported after ingestion of 26 g cocoa [54]. Similarly, levels of 0.2–0.4 µM EC have 
been observed after ingestion of 50 g [55] and 80 g [56] chocolate. In addition, it should 
not be underestimated the potential contribution of EC and flavanol metabolites to the 
biological activity, which is unclear at present; their evaluation will require further 
studies. In this regard, more accurate approaches recently used are the incubation of 
cultured cells with plasma obtained from volunteers consuming the molecule or food of 
interest [57] and the employ of a system based on co-culture of human enterocytes with 
human hepatocytes, which has been proved to resemble a human physiological system 
useful for assay the bioactivity of extracts [58]. 
In summary, EC and CPE possess an insulin-like activity, as they enhanced tyrosine 
phosphorylated and total levels of IR, IRS-1 and IRS-2 and activated PI3K/AKT 
pathway and AMPK at concentrations that are not toxic to hepatic cells and are 
reachable through the diet (Figure 7). We have also revealed a new mechanism by 
which EC and CPE modulate the hepatic gluconeogenesis and PEPCK expression via 
AKT and AMPK (Figure 7). Although further efforts are needed to define the precise 
role of EC and cocoa in the regulation of the insulin pathways in liver cells, a diet rich 
in EC and/or cocoa may be a potential chemopreventive tool useful for the management 
of diabetes. 
 21 
Acknowledgements 
This work was supported by the grants AGL2010-17579 and CSD2007-00063 from the 
Spanish Ministry of Science and Innovation (MICINN). I. Cordero-Herrera is a fellow 
of the FPI predoctoral program of MICINN. 
 
Conflict of interest statement 
The authors have declared no conflict of interest. 
 
 22 
5. References 
[1] Whiting, D. R., Guariguata, L., Weil, C., Shaw, J., IDF Diabetes Atlas: Global 
estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin 
Pract. 2011, 94, 311-321. 
[2] Hanhineva, K., Törrönen, R., Bondia-Pons, I., Pekkinen, J., et al., Impact of dietary 
polyphenols on carbohydrate metabolism. Int J Mol Sci. 2010, 11, 1365-1402. 
[3] Klover, P. J., Mooney, R. A., Hepatocytes: critical for glucose homeostasis. Int J 
Biochem Cell Biol. 2004, 36, 753-758. 
[4] Mihaylova, M. M., Shaw, R. J., The AMPK signalling pathway coordinates cell 
growth, autophagy and metabolism. Nature Cell Biol. 2011, 13, 1016-1023. 
[5] Hardie, D. G., AMP-activated protein kinase-an energy sensor that regulates all 
aspects of cell function. Genes & Develop. 2011, 25, 1895-1908. 
[6] Martin, M. A., Ramos, S., Mateos, R., Granado-Serrano, A. B., et al., Protection of 
human HepG2 cells against oxidative stress by cocoa phenolic extract. J Agric 
Food Chem. 2008, 56, 7765-7772. 
[7] Ramos, S., Cancer chemoprevention and chemotherapy: dietary polyphenols and 
signalling pathways. Mol Nutr Food Res. 2008, 52, 507-526. 
[8] Granado-Serrano, A. B., Martín, M. A., Izquierdo-Pulido, M., Goya, L., et al., 
Molecular mechanisms of (-)-epicatechin and chlorogenic acid on the regulation 
of the apoptotic and survival/proliferation pathways in a human hepatoma cell 
line. J Agric Food Chem. 2007, 55, 2020-2027. 
[9] Granado-Serrano, A. B., Martín, M. A., Haegeman, G., Goya, L., et al., Epicatechin 
induces NF-kB, activator protein-1 (AP-1) and nuclear transcription factor 
erythroid 2p45-related factor-2 (Nrf2) via phosphatidylinositol-3-kinase/protein 
 23 
kinase B (PI3K/AKT) and extracellular regulated kinase (ERK) signalling in 
HepG2 cells. Brit J Nutr. 2010, 103, 168-179. 
[10] Granado-Serrano, A. B., Martín, M. A., Goya, L., Bravo, L., Ramos, S., Time-
course regulation of survival pathways by epicatechin on HepG2 cells. J Nutr 
Biochem. 2009, 20, 115-124. 
[11] Ahmad, F., Khalid, P., Khan, M. M., Rastogi, A. K., Kidwai, J. R., Insulin like 
activity in (-) epicatechin. Acta Diabetol Lat. 1989, 26, 291-300. 
[12] Vazquez-Prieto, M. A., Bettaieb, A., Haj, F. G., Fraga, C. G., Oteiza, P. I., (-)-
Epicatechin prevents TNFα-induced activation of signaling cascades involved in 
inflammation and insulin sensitivity in 3T3-L1 adipocytes. Arch Biochem 
Biophys, doi.org/10.1016/j.abb.2012.02.019. 2012. 
[13] Igarashi, K., Honma, K., Yoshinari, O., Nanjo, F., Hara, Y., Effects of dietary 
catechins on glucose tolerance, blood pressure and oxidative status in Goto-
Kakizaki ratas. J Nutr Sci Vitaminol. 2007, 53, 496-500. 
[14] Kim, M. J., Ryu, G. R., Chung, J. S., Sim, S. S., et al., Protective effects of 
epicatechin against the toxic effects of streptozotocin on rat pancreatic islets: in 
vivo and in vitro Pancreas. 2003, 26, 292-299. 
[15] Taub, P. R., Ramirez-Sanchez, I., Ciaraldi, T. P., Perkins, G., et al., Alterations in 
skeletal muscle indicators of mitochondrial structure and biogenesis in patients 
with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin 
Transl Sci. 2012, 5, 43-47. 
[16] Vinson, J. A., Proch, J., Bose, P., Muchler, S., et al., Chocolate is a powerful ex 
vivo and in vitro antioxidant, antiatherosclerotic agent in an animal model, and a 
significant contributor to antioxidants in the European and American diets. J 
Agric Food Chem. 2006, 54, 8071-8076. 
 24 
[17] Granado-Serrano, A. B., Martín, M. A., Bravo, L., Goya, L., Ramos, S., A diet rich 
in cocoa attenuates N-nitrosodiethylamine-induced liver injury in rats. Food 
Chem Toxicol. 2009, 47, 2499–2506. 
[18] Abril-Gil, M., Massot-Cladera, M., Pérez-Cano, F. J., Castellote, C., et al., A diet 
enriched with cocoa prevents IgE synthesis in a rat allergy model. Pharmacol. 
Res. 2012, 65, 603-608. 
[19] Grassi, D., Desideri, G., Necozione, S., Lippi, C., et al., Blood pressure is reduced 
and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 
15 days of consuming high-polyphenol dark chocolate. J Nutr. 2008, 138, 1671-
1676. 
[20] Hooper, L., Kay, C., Abdelhamid, A., Kroon, P. A., et al., Effects of chocolate, 
cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-
analysis of randomized trials. Am J Clin Nutr. 2012, 95, 740-751. 
[21] Ruzaidi, A. M. M., Abbe, M. M. J., Amin, I., Nawalyah, A. G., Muhajir, H., 
Protective effect of polyphenol-rich extract prepared from Malaysian cocoa 
(Theobroma cacao) on glucose levels and lipid profiles in streptozotocin-induced 
diabetic rats. J Sci Food Agric. 2008, 88, 1142-1447. 
[22] Martín, M. A., Granado-Serrano, A. B., Ramos, S., Izquierdo Pulido, M., et al., 
Cocoa flavonoids up-regulate antioxidant enzyme activity via the ERK1/2 
pathway to protect against oxidative stress-induced apoptosis in HepG2 cells. J 
Nutr Biochem. 2010, 21, 196-205. 
[23] Collins, Q. F., Liu, H. Y., Pi, J., Liu, Z., et al., Epigallocatechin-3-gallate (EGCG), 
a green tea polyphenol, suppresses hepatic gluconeogenesis through 5´-AMP-
activated protein kinase. J Biol Chem. 2007, 282, 30143-30149. 
 25 
[24] Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., et al., Control of hepatic 
gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001, 
413, 131-138. 
[25] Whiteman, E. L., Cho, H., Birnbaum, M. J., Role of Akt/protein kinase B in 
metabolism. TRENDS Endocrinol Metab. 2002, 13, 444-451. 
[26] Brandon, E. F., Bosch, T. M., Deenen, M. J., Levink, R., et al., Validation of in 
vitro cell models used in drug metabolism and transport studies: genotyping of 
cytochrome P450, phase II enzymes and drug transporters polymorphisms in the 
human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma 
(CaCo-2, LS180) cell lines. Toxicol Appl Pharmacol. 2006, 211, 1–10. 
[27] Lin, C. L., Lin, J. K., Epigallocatechin gallate (EGCG) attenuates high glucose-
induced insulin signaling blockade in human HepG2  hepatoma cells. Mol Nutr 
Food Res. 2008, 52, 930-939. 
[28] Nakajima, K., Yamauchi, K., Shigematsu, S., Ikeo, S., et al., Selective attenuation 
of metabolic branch of insulin receptor down-signaling by high glucose in a 
hepatoma cell line, HepG2 cells. J Biol Chem. 2000, 275, 20880–20886. 
[29] Borradaile, N. M., de Dreu, L. E., Huff, M. W., Inhibition of net HepG2 cell 
apolipoprotein B secretion by the citrus flavonoid naringenin involves activation 
of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 
phosphorylation. Diabetes. 2003, 52, 2554-2561. 
[30] Lin, C. L., Huang, H. C., Lin, J. K., Theaflavins attenuate hepatic lipid 
accumulation through activating AMPK in human HepG2 cells. J Lipid Res. 
2007, 48, 2334-2343. 
 26 
[31] Pu, P., Gao, D. M., Mohamed, S., Chen, J., et al., Naringin ameliorates metabolic 
syndrome by activating AMP-activated protein kinase in mice fed a high-fat 
diet. Arch Biochem Biophys. 2012, 518, 61-70. 
[32] Cao, H., Hininger-Favier, I., Kelly, M. A., Benaraba, R., et al., Green tea 
polyphenol extract regulates the expression of genes involved in glucose uptake 
and insulin signaling in rats fed a high fructose diet. J Agric Food Chem. 2007, 
55, 6372-6378. 
[33] Qin, B., Polansky, M. M., Harry, D., Anderson, R. A., Green tea polyphenols 
improve cardiac muscle mRNA and protein levels of signal pathways related to 
insulin and lipid metabolism and inflammation in insulin-resistant rats. Mol Nutr 
Food Res. 2010, 54, S14-S23. 
[34] Montagut, G., Onnockx, S., Vaqué, M., Bladé, C., et al., Oligomers of grape-seed 
procyanidin extract activate the insulin receptor and key targets of the insulin 
signaling pathway differently from insulin. J Nutr Biochem. 2010, 21, 476-481. 
[35] Cai, E. P., Lin, J. K., Epigallocatechin gallate (EGCG) and rutin suppress the 
glucotoxicity through activating IRS2 and AMPK signaling in rat pancreatic β 
cells. J Agric Food Chem. 2009, 57, 9817-9827. 
[36] Min, S. Y., Yang, H., Seo, S. G., Shin, S. H., et al., Cocoa polyphenols suppress 
adipogenesis in vitro and obesity in vivo by targeting insulin receptor. Int J Obes 
(London), doi: 10.1038/ijo.2012.85. 2012. 
[37] Kim, H. S., Noh, J. H., Hong, S. H., Hwang, Y. C., et al., Rosiglitazone stimulates 
the release and synthesis of insulin by enhancing GLUT-2, glucokinase and 
BETA2/NeuroD expression. Biochem Biophys Res Commun. 2008, 367, 623-
629. 
 27 
[38] Vetterli, L., Brun, T., Giovannoni, L., Bosco, D., Maechler, P., Resveratrol 
potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human 
islets through Sirt1 dependent mechanism. J Biol Chem. 2011, 286, 6049-6060. 
[39] Leclerc, I., Lenzner, C., Gourdon, L., Vaulont, S., et al., Hepatocyte nuclear factor-
4alpha involved in type 1 maturity-onset diabetes of the young is a novel target 
of AMP-activated protein kinase. Diabetes. 2001, 50, 1515-1521. 
[40] Ruan, C. T., Lam, S. H., Chi, T. C., Lee, S. S., Su, M. J., Borapetoside C from 
Tinospora crispa improves insulin sensitivity in diabetic mice. Phytomedicine. 
2012, 19, 719-724. 
[41] Takikawa, M., Inoue, S., Horio, F., Tsuda, T., Dietary anthocyanin-rich bilberry 
extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-
activated protein kinase in diabetic mice. J Nutr. 2010, 140, 527-533. 
[42] Zang, M., Xu, S., Maitland-Toolan, K. A., Zuccollo, A., et al., Polyphenols 
stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated 
atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006, 55, 
2180-2191. 
[43] Yuan, H. D., Kim, Y. D., Quan, H. Y., Kim, S. J., et al., Ginsenoside Rg2 induces 
orphan nuclear receptor SHP gene expression and inactivates GSK3b via AMP-
activated protein kinase to inhibit hepatic glucose production in HepG2 cells. 
Chem Biol Interact. 2012, 195, 35-42. 
[44] Kim, S. J., Yuan, H. D., Chung, S. H., Ginsenoside Rg1 suppresses hepatic glucose 
production via AMP-activated protein kinase in HepG2 cells. Biol Pharm Bull. 
2010, 33, 325-328. 
 28 
[45] Zhang, M., Lv, X., Li, J., Meng, Z., et al., Sodium caprate augments the 
hypoglycemic effect of berberine via AMPK in inhibiting hepatic 
gluconeogenesis. Mol Cell Endocrinol. 2012, 363, 122-130. 
[46] Yuan, H. D., Piao, G. C., An active part of Artemisia sacrorum Ledeb. suppresses 
gluconeogenesis through AMPK mediated GSK3β and CREB phosphorylation 
in human HepG2 cells. Biosci Biotechnol Biochem. 2011, 75, 1079-1084. 
[47] Choi, M. S., Jung, U. J., Yeo, J., Kim, M. J., Lee, M. K., Genistein and daidzein 
prevent diabetes onset by elevating insulin level and altering hepatic 
gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) 
mice. Diabetes Metab Res Rev. 2008, 24, 74-81. 
[48] Purushotham, A., Tian, M., Belury, M. A., The citrus fruit flavonoid naringenin 
suppresses hepatic glucose production from Fao hepatoma cells. Mol Nutr Food 
Res. 2009, 53, 300-307. 
[49] Waltner-Law, M. E., Wang, X. L., Law, K., Hall, R. K., et al., Epigallocatechin 
gallate, a constituent of green tea, represses hepatic glucose production. J Biol 
Chem. 2002, 277, 34933-34940. 
[50] Yasui, K., Tanabe, H., Okada, N., Fukutomi, R., et al., Effects of catechin-rich 
green tea on gene expression of gluconeogenic enzymes in rat hepatoma H4IIE 
cells. Biomed Res. 2010, 31, 183-189. 
[51] Prasad, R. C., Herzog, B., Boone, B., Sims, L., Waltner-Law, M., An extract of 
Syzygium aromaticum represses genes encoding hepatic gluconeogenic enzymes. 
J Ethnopharmacol. 2005, 96, 295-301. 
[52] Ramiro, E., Franch, A., Castellote, C., Perez-Cano, F., et al., Flavonoids from 
Theobroma cacao down-regulate inflammatory mediators. J Agric Food Chem. 
2005, 53, 8506-8511. 
 29 
[53] Baba, S., Osakabe, N., Natsume, M., Muto, Y., et al., In vivo comparison of the 
bioavailability of (þ)-catechin, (2)-epicatechin and their mixture in orally 
administered rats. J Nutr. 2001, 131, 2885-2891. 
[54] Holt, R. R., Lazarus, S. A., Sullards, M. C., Zhu, Q. Y., et al., Procyanidin dimer 
B2 [epicatechin-(4-beta-8)-epicatechin] in human plasma after the consumption 
of a flavanol-rich cocoa. Am J Clin Nutr. 2002, 76, 798-804. 
[55] Wang, J. F., Schramm, D. D., Holt, R. R., Ensunsa, J. L., et al., A dose-response 
effect from chocolate consumption on plasma epicatechin and oxidative damage. 
J Nutr. 2000, 130, 2115S-2119S. 
[56] Rein, D., Lotito, S., Holt, R. R., C.L., K., et al., Epicatechin in human plasma: in 
vivo determination and effect of chocolate consumption on plasma oxidation 
status. J Nutr. 2000, 130, 2109S-2114S. 
[57] Canali, R., Ambra, R., Stelitano, C., Mattivi, F., et al., A novel model to study the 
biological effects of red wine at molecular level. Br J Nutr. 2007, 97, 1053-
1058. 
[58] Castell-Auví, A., Motilva, M. J., Macià, A., Torrell, H., et al., Organotypic co-
culture system to study plant extract bioactivity on hepatocytes. Food Chem. 
2010, 122, 775-781. 
 30 
Legends to figures 
 
Figure 1. Effect of EC and CPE on phosphorylated and total levels of IR, IRS-1 and 
IRS-2 in HepG2 cells after 24 h of treatment. (A) Bands of representative experiments. 
Densitometric quantification of (B) p-IR and total IR, (C) p-IRS-1 and total IRS-1 and 
(D) p-IRS-2 and total IRS-2. Protein extracts were subjected to immunoprecipitation (IP) 
with the anti-phospho-tyrosine (P-Tyr) antibody. The resulting immunocomplexes were 
analysed by Western blot (WB) with the anti-IR or IRS-1 or IRS-2 antibody. Values are 
expressed as a percentage relative to the control condition (means ± SD, n=7-9). Equal 
loading of Western blots was ensured by β-actin. Means (for the phosphorylated or total 
protein levels) without a common letter differ (P<0.05). 
 
Figure 2. Effect of EC and CPE on levels of phosphorylated and total AKT, GSK3 and 
GS in HepG2 cells. (A) Bands of representative experiments. Percentage data of (B) p-
AKT/AKT, (C) p-GSK3/GSK3 and (D) pGS/GS ratios relative to controls. Values are 
expressed as a percentage relative to the control condition and are means ± SD, n=6-9. 
Equal loading of Western blots was ensured by β-actin. Means without a common letter 
differ (P<0.05). 
 
Figure 3. Effect of EC and CPE on phosphorylated and total AMPK levels in HepG2 
cells. (A) Bands of representative experiments. (B) Percentage values of p-
AMPK/AMPK ratio relative to the control condition (means ± SD, n=7-8). Equal 
loading of Western blots was ensured by β-actin. Different letters over bars indicate 
statistically significant differences (P<0.05).  
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Figure 4. Effect of EC and CPE on GLUT-2 levels in HepG2 cells. (A) Bands of 
representative experiments. (B) Densitometric quantification of GLUT-2. Values are 
expressed as a percentage relative to the untreated control condition and are means ± SD, 
n=7-8. Equal loading of Western blots was ensured by β-actin. Means without a 
common letter differ (P < 0.05) 
 
Figure 5. Effect of EC and CPE and selective inhibitor LY (LY294002) on levels of 
PEPCK, AKT and AMPK, and glucose production. HepG2 cells were incubated in the 
presence or absence of 25 µM LY for 1 h and later with 10 μM EC or 1 µg/mL CPE for 
24 h. (A) Bands of representative experiments. Percentage data of (B) PEPCK, (C) p-
AKT/AKT and (D) p-AMPK/AMPK relative to the control condition (means ± SD, n=6-
9). Equal loading of Western blots was ensured by β-actin. (E) Glucose production was 
expressed as percent of control are means ± SD of 10-15 different samples per condition. 
Different letters over bars indicate statistically significant differences (P<0.05). 
 
Figure 6. Effect of EC and CPE and selective inhibitor Compound C (Comp. C) on 
levels of PEPCK, AKT and AMPK, and glucose production. HepG2 cells were 
incubated in the presence or absence of 30 µM Comp. C for 1 h and later with 10 μM EC 
or 1 µg/mL CPE for 24 h. (A) Bands of representative experiments. Densitometric 
quantification of (B) PEPCK levels, (C) p-AKT/AKT and (D) p-AMPK/AMPK. Values 
are expressed as a percentage relative to the control condition and are means ± SD, n=6-
10. Equal loading of Western blots was ensured by β-actin. (E) Glucose production was 
expressed as percent of control are means ± SD of 10-16 different samples per condition. 
Means without a common letter differ (P<0.05). 
 
 32 
Figure 7. Schematic overview showing the EC- and CPE-induced insulin and glucose 
signalling pathways analysed in HepG2 cells. Sharp arrows indicate positive inputs 
(activation), whereas a line shows negative inputs (inhibition). 
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Table 1. Effects of EC and CPE on (A) cell viability and (B) cell proliferation. Cell 
viability was determined as relative percent of Crystal Violet stained control cells. Cell 
proliferation was calculated as percentage of the relative increase over the control 
values of BrdU incorporated into genomic DNA. Data represent means  SD of 8-10 
samples. Means for each antioxidant without a common letter differ, P<0.05. 
 
 
 
 
 
 Cell viability 
(% of viable cells) 
Cell proliferation 
(% of controls) 
C 100.5 ± 10.1
a
 100.0 ± 7.8
a
 
EC (μM) 
     1 
     5 
     10 
     20 
 
92.2 ± 6.3
a
 
103.7. ± 5.3
a
 
104.7 ± 10.9
a
 
108.7 ± 7.2
a
 
 
100.8 ± 9.2
a
 
100.2 ± 7.8
a
 
104.1 ± 8.7
a
 
102.4 ± 8.2
a
 
CPE (μg/mL) 
     1 
     5 
    10 
    20 
 
95.0 ± 4.8
a
 
97.3 ± 6.3
a
 
98.0 ± 9.4
a
 
107.2 ± 7.8
a
 
 
93.2 ± 7.5
a
 
93.9 ± 12.6
a
 
97.5 ± 13.3
a
 
91.3 ± 6.4
a
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